Burns & Wound Healing

Introduction

 

Biologic therapies have emerged as a cornerstone in regenerative medicine for wound care. Unlike conventional dressings or topical agents, biologics provide bioactive signaling molecules, extracellular matrix (ECM) scaffolds, and in some cases viable cellular components that stimulate angiogenesis, modulate inflammation, and accelerate tissue repair. Evidence from recent studies demonstrates significant benefit in both chronic non-healing wounds and acute injuries such as burns and surgical defects.

 

Biologic Product Categories in Wound Care

 

• Cellular and Tissue-Based Products (CTPs): Allogeneic skin substitutes (cryopreserved placental membranes, amniotic membranes, dermal allografts) provide structural ECM and growth factors. Stem cell–containing allografts (perinatal tissues with mesenchymal stem cells) contribute immunomodulatory and angiogenic activity.
• Extracellular Matrix (ECM) Scaffolds: Derived from human or animal sources (porcine small intestine submucosa, human dermis). Provide a 3D scaffold that supports fibroblast migration, vascular ingrowth, and keratinocyte re-epithelialization.
• Biologic Dressings & Growth Factor Preparations: Recombinant growth factors (becaplermin gel, PDGF-BB). Platelet-derived products (PRP, platelet lysate).

 

Clinical Applications

 

1. Chronic Non-Healing Wounds

Ideal candidates:

• Diabetic foot ulcers (DFUs): Patients with Wagner grade II or higher DFUs refractory to standard wound care (off-loading, debridement, infection control). Multiple RCTs show amniotic/chorionic membrane allografts significantly improve healing rates compared with standard therapy.
• Venous leg ulcers (VLUs): Biologic matrices improve closure rates when added to compression therapy.
• Pressure ulcers: In selected patients, biologics accelerate closure by restoring ECM signaling.

Supporting Literature:

• Zelen et al., Int Wound J (2016): Amniotic membrane allografts demonstrated 70–85% closure in chronic DFUs vs 30–35% with standard of care.
• Serena et al., Adv Wound Care (2020): Placental allografts improved granulation tissue formation and epithelialization in refractory VLUs.

 

2. Acute Wounds and Burns

Ideal candidates:

• Partial-thickness burns: Application of amniotic membrane or ECM substitutes reduces pain, infection risk, and time to re-epithelialization.
• Full-thickness burns requiring grafting: Biologic scaffolds can be used as a dermal substitute before autograft placement.
• Surgical or traumatic wounds: Especially where tissue loss or delayed closure is expected.

Supporting Literature:

• Mohammadi et al., Burns (2019): Amniotic membrane significantly decreased healing time and pain in pediatric partial-thickness burns.
• Branski et al., Ann Plast Surg (2013): ECM scaffolds improved outcomes in acute burn reconstruction, reducing contracture and hypertrophic scarring.

 

Patient Selection Criteria

 

Inclusion

• Chronic wounds (>4–6 weeks non-healing despite standard care).
• DFUs, VLUs, pressure ulcers unresponsive to conventional therapy.
• Acute traumatic wounds or burns with large surface area or depth.
• Post-surgical wounds with dehiscence or poor vascularity.
• Patients without active, uncontrolled systemic infection.

 

Exclusion / Relative Contraindications

• Untreated osteomyelitis.
• Active malignancy in or adjacent to wound site.
• Severe peripheral arterial disease not revascularized (ABI <0.4).
• Known hypersensitivity to product components.

 

Mechanism of Action of Biologics in Wound Healing

 

• Angiogenesis – Release of VEGF, PDGF, and bFGF enhances new vessel formation.
• Modulation of Inflammation – MSCs secrete IL-10, TGF-β, and prostaglandin E2, reducing chronic inflammatory signaling.
• Cell Recruitment & Proliferation – Bioactive ECM scaffolds provide integrin-binding sites for fibroblasts, keratinocytes, and endothelial cells.
• Antimicrobial Activity – Amniotic tissues contain defensins and lysozyme, reducing bacterial load.
• Scar Reduction – ECM and amniotic membranes regulate fibroblast activity, decreasing hypertrophic scarring in burns.

 

Conclusion

 

Biologic therapies represent a paradigm shift in wound management, offering regenerative solutions where conventional therapies fall short. The strongest evidence supports their use in:
• Diabetic foot ulcers and other chronic non-healing wounds refractory to standard of care.
• Partial and full-thickness burns, where they reduce healing time, pain, and scarring.
• Surgical and traumatic wounds requiring advanced closure strategies.

Proper patient selection—eliminating uncontrolled infection, correcting vascular insufficiency, and integrating biologics into a comprehensive wound care plan—is essential for optimizing outcomes.